Paper2553992
Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors.
Tan KB and 4 others. J Natl Cancer Inst, 1989. Cited by 188 papers, by iCite.
Cite this record
ConductScience Library. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. Papers, record 2553992. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2553992
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors.
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Amsacrine | Major topic |
| Camptothecin | Major topic |
| DNA Topoisomerases, Type I | Major topic |
| DNA Topoisomerases, Type II | Major topic |
| Gene Rearrangement | Major topic |
| Leukemia P388 | Major topic |
| Leukemia, Experimental | Major topic |
| Alleles | |
| Animals | |
| Drug Resistance | |
| Gene Expression Regulation | |
| Methylation | |
| Methyltransferases | |
| Mice | |
| RNA, Messenger | |
| Topoisomerase I Inhibitors | |
| Topoisomerase II Inhibitors | |
| Transcription, Genetic |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| CA-40884 | NCI NIH HHS | United States | PubMed |
Source PubMed
Cited by29
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 188 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 36408699 | Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01). | Thorac Cancer | 2023 | https://conductscience.org/library/papers/36408699 | PubMed |
| 36248326 | Clinical impact of amrubicin monotherapy in patients with relapsed small cell lung cancer: a multicenter retrospective study. | Transl Lung Cancer Res | 2022 | https://conductscience.org/library/papers/36248326 | PubMed |
| 35740594 | Drug Resistance in Colorectal Cancer: From Mechanism to Clinic. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35740594 | PubMed |
| 28454315 | Correlation between the efficacy of amrubicin and the previous chemotherapy regimen for relapsed small cell lung cancer. | Oncol Lett | 2017 | https://conductscience.org/library/papers/28454315 | PubMed |
| 26270258 | Nanodrug Formed by Coassembly of Dual Anticancer Drugs to Inhibit Cancer Cell Drug Resistance. | ACS Appl Mater Interfaces | 2015 | https://conductscience.org/library/papers/26270258 | PubMed |
| 26199623 | Amrubicin Monotherapy for Patients with Platinum-Refractory Gastroenteropancreatic Neuroendocrine Carcinoma. | Gastroenterol Res Pract | 2015 | https://conductscience.org/library/papers/26199623 | PubMed |
| 24875756 | Folding graft copolymer with pendant drug segments for co-delivery of anticancer drugs. | Biomaterials | 2014 | https://conductscience.org/library/papers/24875756 | PubMed |
| 23215027 | Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest. | Mol Pharm | 2013 | https://conductscience.org/library/papers/23215027 | PubMed |
| 22966396 | Methylated BNIP3 gene in colorectal cancer prognosis. | Oncol Lett | 2010 | https://conductscience.org/library/papers/22966396 | PubMed |
| 21159664 | Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma. | Cancer Res | 2011 | https://conductscience.org/library/papers/21159664 | PubMed |
| 21069340 | Lack of in vivo cross-resistance with 4'-thio-ara-C against drug-resistant murine P388 and L1210 leukemias. | Cancer Chemother Pharmacol | 2011 | https://conductscience.org/library/papers/21069340 | PubMed |
| 19332675 | Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane. | Antimicrob Agents Chemother | 2009 | https://conductscience.org/library/papers/19332675 | PubMed |
| 17984197 | Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan. | Mol Pharmacol | 2008 | https://conductscience.org/library/papers/17984197 | PubMed |
| 17479288 | Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial. | J Cancer Res Clin Oncol | 2007 | https://conductscience.org/library/papers/17479288 | PubMed |
| 15793124 | Topoisomerase I amino acid substitutions, Gly185Arg and Asp325Glu, confer camptothecin resistance in Leishmania donovani. | Antimicrob Agents Chemother | 2005 | https://conductscience.org/library/papers/15793124 | PubMed |
| 12743815 | Expression of drug resistance related proteins in sarcomas of the pulmonary artery and poorly differentiated leiomyosarcomas of other origin. | Virchows Arch | 2003 | https://conductscience.org/library/papers/12743815 | PubMed |
| 11592782 | Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants. | Br J Cancer | 2001 | https://conductscience.org/library/papers/11592782 | PubMed |
| 10604726 | Reversal of MDR1-associated resistance to topotecan by PAK-200S, a new dihydropyridine analogue, in human cancer cell lines. | Br J Cancer | 1999 | https://conductscience.org/library/papers/10604726 | PubMed |
| 9414662 | Antitumor activity of a novel quinoline derivative, TAS-103, with inhibitory effects on topoisomerases I and II. | Jpn J Cancer Res | 1997 | https://conductscience.org/library/papers/9414662 | PubMed |
| 9400949 | Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. | Br J Cancer | 1997 | https://conductscience.org/library/papers/9400949 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2553992
GET https://conductscience.org/api/papers/v1/2553992/cited_by?page=2